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doi:10.1016/j.ejvs.2008.02.009Abstract Introduction: The practice of carotid endarterectomy (CEA) with patch angioplasty
is more effective compared to primary closure. However, the type of patch material remains
a controversy. The Fluoropassiv thin wall carotid patch is a polyester patch with an interpe-
netrating, nanometer-scale, solvent-applied surface modification, based on a biocompatible
fluoropolymer. The present pilot study is the first clinical trial evaluating results of CEA with
Fluoropassiv versus venous patch.
Materials/Methods: Eighty-seven patients were randomized to 42 Fluoropassiv patching and
45 venous patching. Patients were observed by a vascular surgeon and a neurologist and
scanned using duplex ultrasound with a follow-up of 2 years. No patients were lost to
follow-up. Restenosis was defined as a Peak Systolic Velocity ratio >2.6, lumen reduction
>50%.
Results: Perioperative stroke rate was 2.4% in the Fluoropassiv group and 8.9% in the venous
group (pZ 0.02; 1 regressive, 4 non-regressive strokes). Multivariate analysis showed that
bilateral carotid stenosis and stroke as indication for CEA were related to perioperative stroke.
There was no link between perioperative stroke and patch type after correction for these fac-
tors. Patch type had no influence on operation time, clamp time, cranial nerve damage, hyper-
tension, hematoma, infections, time to discharge, or early thromboembolic events. There
were no significant differences between the Fluoropassiv and the venous group for cumula-
tive mortality (respectively 4.4 vs 4.8%), patch occlusion (4.8 vs 2.2%), or stroke rate during 2
year follow-up (2.2 vs 2.4%).
Conclusion: This first clinical study with the Fluoropassiv thin wall carotid patch showed no
enhanced thrombogenicity compared to a venous patch. The Fluoropassiv patch is not
related to a higher rate of postoperative bleeding events either.
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The effectiveness of carotid endarterectomy (CEA) in symp-
tomatic and asymptomatic patients for the prevention of
cerebral infarction has been clearly demonstrated.1e4 The
practice of CEA with patch angioplasty has been shown to
be more effective compared to primary closure.5 Patching
decreases the rate of perioperative and postoperative stroke
and late recurrent stenosis. However, the type of patch ma-
terial remains a controversy.6 Patch angioplasty may be per-
formed with autologous vein or synthetic material. Several
studies have shown comparable perioperative and long-
term results with vein and polytetrafluoroethylene (PTFE;
Gore-Tex;WLGoreandAssociates, Flagstaff, AZ,USA) patch-
ing.7,8 Theadvantages of synthetic patches over vein patches
are decreased incidence of aneurysmal dilatation and patch
rupture, patchharvesting complications, andavailability.9,10
PTFE patching does have the disadvantage of prolonged he-
mostatic time.11 Knitted polyester patches (Boston Scientific
Corp, Natick, MA, USA) have been advocated to avoid this,
but are related to higher rates of perioperative strokes and
late recurrent stenosis.12
The Fluoropassiv thin wall carotid patch (Vascutek,
a Terumo Company, Scotland, UK) is a polyester patch with
an interpenetrating nanometer-scale, solvent-applied sur-
face modification, based on a biocompatible fluoropolymer
and combining biocompatibility with reduced hemostatic
time. In vitro and animal studies confirm that Fluoropassiv
exhibits reduced thrombogenicity and suture hole bleeding
compared to other synthetic materials.13 We hypothesize
that this new synthetic patch shows comparable postoper-
ative results (i.e. neurological events, recurrent stenosis)
to venous patches, but with the advantages of synthetic
over venous patches as mentioned above (e.g. patch har-
vesting complications). The present pilot study is the first
clinical trial evaluating early and long-term results of CEA
with the Fluoropassiv thin wall carotid patch as it
compares these results to the use of a venous patch.
Materials and Methods
Study design
The study was a prospective randomized clinical trial
carried out at a single center between 2000 and 2004.
Patients gave informed consent. Randomization was per-
formed by using sealed opaque envelopes containing in-
dication for venous or Fluoropassiv patch. An envelop was
drawn at the start of surgery and the study controller
notified the surgeon of the procedure to be performed. All
patients included had symptomatic carotid stenosis (>70%).
Eighty-eight consecutive patients undergoing CEA be-
tween September 2000 and March 2004 were eligible for
randomization (Fig. 1). Patients were excluded from this
trial on the following criteria: known allergies to patch
products used, previous ipsilateral carotid surgery, bilateral
carotid endarterectomy, progressive neurological events
one month prior to surgery (e.g. crescendo transient ische-
mic attack), and/or hospitalization for heart failure in pre-
vious six months. At the beginning of this study, progressive
neurological events were still regarded as an indication fordelay of CEA, based upon the results of several retrospec-
tive studies.14,15 For uniformity of the present study we
continued to exclude such patients, although the discussion
on timing of CEA continued. Based on these exclusion crite-
ria, one patient was excluded. Eighty-seven patients were
randomized to Fluoropassiv patching (nZ 42) and venous
patching (nZ 45). No crossover was observed during the
study. No patients were lost to follow-up. The study was
approved by the local medical ethical committee.
Before surgery, all patients underwent carotid duplex
ultrasound and angiography to determine carotid stenosis.
Baseline preoperative risk factors for cardiovascular disease
(e.g. diabetes and hypertension), demographic character-
istics and antiplatelet therapy were determined (Table 1).
Indications for surgery were categorized into: transient
ischemic attack (TIA), amaurosis fugax, regressive stroke
and non-regressive stroke.
Operative technique
All patients continued antiplatelet therapy (Dipyridamol
(Persantin) 150 mg twice daily)and Carbasalaatcalcium
(Ascal 80 mg daily) and the patient’s usual medication
were administered on the morning of surgery. CEAs were
performed by two surgeons under general anesthesia and
systemic heparin use (usually 5000 units, depending on
weight). Intraoperative shunting was used when transcranial
doppler (TCD) showed more than 60% reduction in cerebral
flow or when Electronic Encephalography (EEG) revealed
significant abnormalities during pre-clamping. Endarterecto-
mies were extended beyond grossly diseased intima. Patients
randomizedtovenouspatchhadasegmentofgreat saphenous
vein harvested at the ankle-lower leg, which was judged
excellent (i.e. no proximal great saphenous vein was used).
Fluoropassiv thin wall carotid (8 mm width, 0.1 mm thick-
ness)andvenouspatchesweresuturedwith6-0polypropylene
sutures (Prolene, Ethicon, Hamburg, Germany), tacking su-
tures at the distal endpoint were not used. Thrombin-soaked
oxidized cellulose and digital pressure were used to stop any
bleeding points prior to closure in the Fluoropassiv group.
No protamine was given at the end of surgery. Operative
and clamping time were recorded. All patients continued
antiplatelet therapy postoperatively and Nadroparine cal-
cium (Fraxiparine 5700 IU/0.6 ml daily) during hospital stay.
Follow-up protocol
All patients were observed by a vascular surgeon and placed
postoperatively to a high-dependency unit. Any new neu-
rological deficit lasting longer than 24 hours was classified
as stroke by a neurologist. These patients were evaluated
by computed tomography and duplex ultrasound scanning.
All patients visited the outpatient clinic for clinical vascular
examination and neurological evaluation, and received
duplex ultrasound 6 weeks and 6, 12 and 24 months after
surgery. All examinations were performed by an operator
blinded for type of patch used. Recurrent stenosis was
defined as Peak Systolic Velocity (PSV) ratio >2.6 or lumen
diameter reduction >50%. Lumen diameter at patch loca-
tion was also followed at the same time for analysis of
venous patch dilatation.
Figure 1 Randomization flow chart.
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asymptomatic recurrent stenosis/acute thrombosis at CEA
location according to the Ad Hoc Committee on Suggested
Standards for Reports Dealing with Cerebrovascular Disease,
and localwound complications (e.g. nerve damage, infection,
pain).Patientswereasked tocompleteavisual analoguescore
(range 1e10) for neck and ankle pain at six weeks after CEA.
Statistical methods
Comparison between groups was performed with student t-
test or Mann-Whitney U test for non-normally distributed
variables, and correlations were analyzed with Spearman
rankmethod.Multivariate (logistic) regression analyseswere
performed to determine independent links of variables with
stroke rate. The primary endpoint of this trial was neurolog-
ical event rates. Secondary endpoints were late recurrent
stenosis, acute thrombosis at CEA location, mortality, local
wound complications and lumen diameter changes at patch
location. Significance was defined as p< 0.05.
Results
Baseline
Table 1 summarizes demographic and clinical characteris-
tics. All patients underwent CEA for symptomatic carotidstenosis (>70%). The indication for CEA showed significant
differences with more preoperative TIAs in the venous
group (77.8% vs 50%, pZ 0.03) and more regressive strokes
in the Fluoropassiv group (47.6% vs 17.8%, pZ 0.03). Ap-
proximately 83% of all patients had a carotid stenosis of
80% or more, which was comparable between both groups.
The number of patients with bilateral carotid stenosis was
almost 3 times higher in the venous group (26.7% vs 9.5%,
p< 0.01).
Table 2 shows the perioperative characteristics. As
noted, mean operation time was 100 minutes in the Fluoro-
passiv group and 93 minutes in the venous group. The
clamping time was also comparable, 39 minutes for the Flu-
oropassiv group vs 38 minutes for the venous group. Peri-
operative intracerebral flow (TCD) was not significantly
different between both groups, and four patients in each
group received selective shunting.
Perioperative stroke rate was significantly higher in the
venous group (8.9%) than in the Fluoropassiv group (2.4%;
pZ 0.02; Table 2). Of the four perioperative strokes in the
venous group, three were non-regressive and one regres-
sive. One perioperative stroke in both groups was related
to acute thrombosis at the site of CEA, and these mani-
fested at the recovery room. All other perioperative strokes
manifested 1e4 days after surgery and showed no abnor-
malities with carotid duplex ultrasound. Multivariate logis-
tic regression analysis showed that perioperative stroke
rate was independently related to the presence of bilateral
Table 1 Patient characteristics
Patch Type
Vein (nZ 45) Fluoropassiv (nZ 42)
Age (yr) 67 8 66 8 pZ 0.7
BMI (kg/m2) 27 0.4 28 0.4 pZ 0.7
Gender e male/female (n) 35/10 34/8 pZ 0.6
CHD (n/%) 26 (58) 24 (57) pZ 0.6
PAOD (n/%) 16 (35.6) 13 (31) pZ 0.5
Pulmonary disease (n/%) 6 (13.3) 5 (12) pZ 0.7
Hyperlipidemia (n/%) 27 (60) 22 (52.4) pZ 0.4
Hypertension (n/%) 33 (73) 31 (73.8) pZ 0.6
Diabetes mellitus (n/%) 9 (20) 13 (31) pZ 0.2
Smoking (n/%) 18 (40) 23 (55) pZ 0.1
Preoperative antiplatelet therapy (n/%) 45 (100) 42 (100) e
CEA Indication:
Asymptomatic (n/%) 0 (0) 0 (0) e
TIA or AF (n/%) 35 (77.8) 21 (50) pZ 0.03
Regressive stroke (n/%) 8 (17.8) 20 (47.6) pZ 0.03
Non-regressive stroke (n/%) 2 (4.4) 1 (2.4) pZ 0.2
Degree of carotid stenosis
70e79% (n/%) 7 (15.6) 7 (16.8) pZ 0.8
80e99% (n/%) 38 (84.4) 35 (83.2) pZ 0.6
Bilateral carotid stenosis (n/%) 12 4 p< 0.01
Mean SD; BMI Z Body Mass Index; CHDZCoronary Heart Disease; PAOD Z Peripheral Arterial Occlusive Disease; TIA Z Transient
Ischemic Attack; AF Z amaurosis fugax; CEA Z carotid endarterectomy.
48 R. Meerwaldt et al.carotid stenosis (odds ratio (OR) 3.4 (95% CI 1,8e4,9)) and
to stroke as the indication for CEA (OR 3,1 (95% CI 1,3e
4,8); p< 0.01). There was no link between perioperative
stroke rate and patch type after correction for differences
in bilateral carotid stenosis and indication for CEA.Table 2 Perioperative characteristics and events
Patch Ty
Vein (nZ
ASA score 1/2/3/4 (n) 0/8/36/1
Total operation time (min) 93 25
Total clamp time (min) 38 10
Shunt (n/%) 4 (8.9)
Intracerebral flow during clamp (%)# 80 20
Intracerebral flow after clamp (%)# 125 20
Patch length (mm) 35 10.1
Neck re-exploration (n/%) 3 (6.7)
Neck hematoma at re-exploration (n/%) 2 (4.4)
Transfusion required (n/%) 3 (6.7)
Hypoglossus nerve damage (n/%) 2 (4.4)
Other local nerve damage (n/%) 0 (0)
TIA (n/%) 0 (0)
Regressive stroke (n/%) 1 (2.2)
Non-regressive stroke (n/%) 3 (6.7)
Hypertensive crisis (n/%) 2 (4.4)
Occlusion (n/%) 1 (2.2)
Mortality (n/%) 1 (2.2)
Median day discharge (95% CI) 3 (3.1e3
Mean SD; ASA Z American Association Anesthetist score; TIA Z tra
# Flow measured with transcranial doppler as a ratio to flow beforeMore patients in the Fluoropassiv group (14.3%) needed
re-exploration for suspected neck hematoma compared to
the venous group (6.7%; pZ 0.03), but no neck infections
occurred. Of these nine patients, only two in the venous
group and three in the Fluoropassiv group actually hadpe
45) Fluoropassiv (nZ 42)
0/7/33/2 pZ 0.7
100 21 pZ 0.1
39 8 pZ 0.8
4 (9.5) pZ 0.9
86 23 pZ 0.4
115 23 pZ 0.3
34 10.2 pZ 0.8
6 (14.3) pZ 0.03
3 (7.1) pZ 0.3
3 (7.1) pZ 0.8
3 (7.1) pZ 0.2
0 (0) e
0 (0) e
0 (0) pZ 0.3
1 (2.4) pZ 0.02
1 (2.4) pZ 0.6
1 (2.4) pZ 0.8
0 (0) pZ 0.3
.5) 3 (3.2e3.5) pZ 0.7
nsient ischemic attack.
clamping.
Table 3 Week 6 postoperative complications and lumen diameters
Patch Type
Vein (nZ 45) Fluoropassiv (nZ 42)
Neck infection (n/%) 0 (0) 0 (0)
New neurological deficits (n/%) 0 (0) 0 (0)
Recurrent stenosis (n/%) 0 (0) 0 (0)
Thrombosis CEA location (n/%) 0 (0) 0 (0)
Mean lumen diameter at patch location (mm SD) 11.6 2.1 10.5 1.9 pZ 0.01
Wound healing disturbance at ankle (n/%) 5 (11.1) e
Pain at ankle (n/%) 10 (22.2) e
Median neck VAS score (95% CI) 1 (1.1e1.5) 1 (1.0e1.6) pZ 0.9
Median ankle VAS score (95% CI) 3 (3.3e3.5) e
Recurrent stenosis Z Peak Systolic Velocity Ratio> 2.6 of lumen reduction >50%; New neurological deficits are transient ischemic at-
tacks and/or stroke; VAS Z visual analog score (1e10).
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edema. Patch type did not influence requirements for
treating early postoperative hypertension, transfusion
requirements or time to hospital discharge.
Six weeks follow-up
NoTIAs or strokes occurred during the next 6weeks of follow-
up (Table 3). All survivors underwent carotid duplex ultra-
sound 6weeks after CEA. Therewereno patientswith carotid
recurrent stenosis or acute thrombosis in either group (all
PSV ratio<2.6 and lumen reduction<50% at patch location).
Mean diameter at the location of the patch was significantlyTable 4 Thromboembolic events and mortality during follow-u
Follow-up Patch Type
Period
Vein (nZ 45) Fluoropassiv
6 months
TIA (n/%) 0 (0) 0 (0)
Stroke (n/%) 0 (0) 0 (0)
Recurrent stenosis (n/%) 0 (0) 0 (0)
Thrombosis CEA location (n/%) 0 (0) 0 (0)
Mortality (n/%) 0 (0) 0 (0)
12 months
TIA (n/%) 2 (4.4) 0 (0)
Stroke (n/%) 0 (0) 0 (0)
Recurrent stenosis (n/%) 0 (0) 0 (0)
Thrombosis CEA location (n/%) 0 (0) 0 (0)
Mortality (n/%) 0 (0) 0 (0)
24 months
TIA (n/%) 1 (2.2) 0 (0)
Stroke (n/%) 1 (2.2) 1 (2.4)
Recurrent stenosis (n/%) 0 (0) 0 (0)
Thrombosis CEA location (n/%) 0 (0.0) 1 (2.4)
Mortality (n/%) 1 (2.2) 2 (4.8)
Cumulative is including direct postoperative events; TIAZ Transient I
lumen reduction >50%; p-values for cumulative data.higher in the venous group (11.6 SD 2.1 mm) compared to
the Fluoropassiv group (10.5 1.9 mm, pZ 0.01).
In the venous group 22.2% complained of pain at the
ankle wound. Approximately 11% of them had wound
healing abnormalities at the ankle (e.g. infection, delayed
healing). Multivariate regression analysis showed that
smoking, presence of diabetes mellitus and a history of
peripheral artery occlusive disease were independently
related to wound healing abnormalities at the ankle
(p< 0.01). There were no cervical wound complication in
both groups. The median analogue score for neck pain
was 1 (95% CI 1.0e1.6) in the venous group and 1 (95% CI,
1.1e1.5) in the Fluoropassiv group. The median analoguep
Cumulative
 (nZ 42) Vein (nZ 45) Fluoropassiv (nZ 42)
0 (0) 0 (0) e
4 (8.9) 1 (2.4) pZ 0.02
0 (0) 0 (0) e
1 (2.2) 1 (2.4) pZ 0.8
1 (2.2) 0 (0) pZ 0.3
2 (4.4) 0 (0) pZ 0.09
4 (8.9) 1 (2.4) pZ 0.02
0 (0) 0 (0) e
1 (2.2) 1 (2.4) pZ 0.8
1 (2.2) 0 (0) pZ 0.3
3 (6.6) 0 (0) pZ 0.05
5 (11) 2 (4.8) pZ 0.06
0 (0) 0 (0) e
1 (2.2) 2 (4.8) pZ 0.8
2 (4.4) 2 (4.8) pZ 0.9
schemic Attack; Recurrent stenosisZ Peak Systolic Ratio> 2.6 or
Figure 2 (a) Box plots of lumen diameter (mm) at patch lo-
cation during duplex ultrasound surveillance for 2 years follow-
up, (b) box plots of the ratio of lumen diameter at patch loca-
tion is the lumen diameter at a specific time compared to the
diameter at 6 weeks follow-up. At the specific times, the box
plots on the left (filled with dots) show the venous group re-
sults; the box plots on the right (filled with stripes) show the
results of the Fluoropassiv group. Box plots also show
outliers.
50 R. Meerwaldt et al.score for ankle pain was 3 (95% CI 3.3e3.5) in the venous
group.
Long-term follow-up
Table 4 shows the results of the two year follow-up period.
No patients were lost to follow-up. The overall survivalrate, including perioperative events, was 95.4%. The cumu-
lative survival rate after two years follow-up was 95.6% in
the venous group and 95.2% in the Fluoropassiv group.
There were no significant differences in stroke rate
between both patch types, except for TIAs. Patients who
received a venous patch had more ipsilateral TIAs after
one and two years follow-up compared to those who
received the Fluoropassiv patch. One of these patients
in the venous group developed a stroke after two years.
The ultrasound duplex analysis of these patients showed
no abnormalities (i.e. no recurrent stenosis/thrombosis or
aneurysmatic dilatation). There were no obvious differ-
ences in patient characteristics compared to the whole
venous group either. There was one late thrombosis of
the internal carotid artery in the Fluoropassiv group,
which also resulted in an ipsilateral non-regressive stroke.
Previous duplex ultrasound analysis in this patient showed
a nonsignificant recurrent stenosis of 40%. No late hemor-
rhage, patch infection or patch rupture occurred.
Figure 2 shows the results of the lumen diameter analy-
sis at patch location. In both groups there was a minimal re-
duction in mean lumen diameter (mean reduction of <10%).
To further analyze changes in diameter, the lumen diame-
ters were compared as a ratio to the diameter at 6 weeks
follow-up (initial postoperative duplex ultrasound measure-
ment). The highest reduction in lumen diameter was 40%,
as observed in three patients from the venous group and
three patients from the Fluoropassiv group. A few pa-
tients in the venous group developed an increase in lumen
diameter at patch location of up to 150%. There were no
patients in either group with a late recurrent stenosis
(PSV ratio >2.6).Discussion
Several studies have shown that CEA with patch angioplasty
is superior to primary closure.5 A systematic review by the
Cochrane Collaboration showed that a policy of routine
patching results in a threefold to fourfold excess reduction
in perioperative and postoperative stroke and recurrent ste-
nosis. Much debate remains regarding the type of patch to
be used though.6 Most randomized trials to date have shown
that venous patches are not ‘‘safer’’ than synthetic patches
(especially PTFE) in terms of neurological events.6e8,16e18
However, one trial by Aburahma et al. shows a benefit of
PTFE over polyester in terms of 30-days stroke rate and
postoperative recurrent stenosis.19 The present study has
shown no evidence that the early (6-week) risk for thrombo-
genic complications is higher in the Fluoropassiv patch
than in the venous patch.
The perioperative stroke rate in the Fluoropassiv group
is comparable to reports onmost other synthetic patches and
even lower compared to (Hemashield) polyester
patches.12,20 However, the perioperative stroke rate in the
venous group seems high. Multivariate analysis showed that
both bilateral carotid stenosis and stroke as indications for
CEA were related to the risk of perioperative stroke. Halm
et al. have shown that these clinical factors indeed increase
the risk for perioperative complications (stroke and death)
with a comparable odds ratio as described in our study.21
This might explain the high rate of perioperative stroke in
Fluoropassiv Patch in Carotid Endarterectomy 51the venous group, since bilateral carotid stenosis was 3 times
more prevalent in the venous group compared to the Fluoro-
passiv group. There was no link between perioperative
stroke rate and patch type after correction for differences
in bilateral carotid stenosis and indication for CEA.
Furthermore, all patients in this trial had symptomatic
carotid stenosis, high comorbidity scores and high degrees
of carotid stenosis. As a consequence, they were at
a ‘‘high’’ risk for complications. A Cochrane analysis in
2002 concluded that there was not enough evidence to
support or refute routine use of shunting during CEA.22 In
the present study, patients did receive selectively a shunt,
based upon TCD measurements and EEG monitoring for ce-
rebral perfusion analysis. However, TCD velocity measure-
ments and EEG monitoring are not always a reliable
indicator of clamping ischemia.23,24
There were no differences in stroke and mortality rates
between both groups during long-term follow-up. Other
randomized trials have concluded the same when compar-
ing vein to prosthetic material.20,25 Naylor et al. showed
that there is more to preventing postoperative strokes
than debates on patching and shunting, such as antiplatelet
therapy.26 Hayes et al. hypothesized that thromboembolic
events are not entirely patch-related, but are also a mea-
sure of a patient’s prothrombotic state.27,28 Importantly,
there is more debate on the risk for late recurrent stenosis
in patients receiving vein or prosthetic patches. Naylor
et al. showed a higher risk for recurrent stenosis in patients
receiving Dacron patches compared to venous patches,
while Rahma et al. showed a higher risk in patients with ve-
nous patches compared to PTFE patches.7,20 In our study,
patients were serially followed-up by duplex ultrasound
for two years. No patients in the venous or the Fluoropas-
siv group developed a late recurrent stenosis. Impor-
tantly, the one patient in the Fluoropassiv group with
a late thrombosis showed no abnormalities (significant re-
current stenosis) on preceding duplex ultrasound surveil-
lance. On the other hand, the mean lumen diameter was
higher in the venous group, and some patients showed an
increase in lumen diameter of up to 150%. Wheeler et al.
showed previously that with use of venous material the lu-
men diameter may indeed increase with time.29 Yamamoto
et al. even demonstrated that aneurysmatic dilatation may
lead to new thromboembolic events, i.e. TIA or stroke.10
Although some of our patients developed TIAs in the venous
group after 2 years follow-up, none of them had an aneur-
ysmatic dilatation of the patch.
Patch type had no influence on mortality, operation and
clamping time, cranial nerve injury, neck wound pain, neck
hematoma and time to hospital discharge. No patients
sustained patch rupture or infection during follow-up.
However, there were more early re-explorations of the
neck for swelling in the Fluoropassiv group (14.3%). These
were not related to a higher rate of neck hematoma in this
group. In some of the patients with neck swelling the
wound was re-explored and found to be hemostatic without
evidence for hematoma, but subcutaneous tissues were
markedly edematous. Two patients in the Fluoropassiv
group used angiotensin-converting enzyme (ACE) inhibitors,
and the use of ACE inhibitors has been described to be
related to angioedema after CEA and other head-neck
procedures.30Other wound complications observed were those at the
ankle for venous harvesting. In the present study, over 22% of
the patients still complained about pain at the ankle/lower
leg, six weeks after surgery. Athanasiou et al. analyzed
wound healing disturbances in minimally invasive vein har-
vesting for coronary bypass surgery.31 In a meta-analysis of
prospective randomized trials, they reported comparable
numbers of patients with ankle wound complications as in
our study (hematoma, skin necrosis, edema). Patients in
need of coronary bypass surgery or CEA are of course those
with systemic atherosclerosis which makes them liable to
wound complications, especially at the ankle. Smoking,
presence of diabetes mellitus and a history of peripheral
artery occlusive disease were all independently related to
wound complications at the ankle in our study.
A limitation of the present study is a possible lack in
power to detect differences in stroke rates. The differ-
ences in incidence of perioperative and long-term stroke
are probably too small between different types of patches,
as concluded e.g. by the Cochrane systematic review.6 Any
study to reliably detect such a difference would have to be
quite vast, and the clinical relevance would probably be
small. Power analyses by others have also confirmed that
trials intended to show clinically relevant differences be-
tween different types of patches would need a very large
population and long-term inclusion.25 Importantly, this
study was not intended to show a superior effect of the Flu-
oropassiv patch compared to a venous patch. We con-
ducted this pilot study to test the safety of the new
Fluoropassiv patch in CEA.
In conclusion, this first clinical study with the Fluoro-
passiv thin wall carotid patch showed no enhanced
thrombogenicity in the early and long-term postoperative
period compared to a venous patch. The Fluoropassiv
patch is not related to a higher rate of postoperative
bleeding events either, as previously observed by PTFE
patches. A continuing analysis of this new patch in daily
practice may help identify its benefits compared to other
patches in CEA.
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